170 related articles for article (PubMed ID: 17943230)
1. Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
Gounder MK; Nazar AS; Saleem A; Pungaliya P; Kulkarni D; Versace R; Rubin EH
Invest New Drugs; 2008 Jun; 26(3):205-13. PubMed ID: 17943230
[TBL] [Abstract][Full Text] [Related]
2. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
[TBL] [Abstract][Full Text] [Related]
3. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
[TBL] [Abstract][Full Text] [Related]
4. The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
Di Francesco AM; Riccardi A; Barone G; Rutella S; Meco D; Frapolli R; Zucchetti M; D'Incalci M; Pisano C; Carminati P; Riccardi R
Biochem Pharmacol; 2005 Oct; 70(8):1125-36. PubMed ID: 16139802
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
[TBL] [Abstract][Full Text] [Related]
6. Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
Ulivi P; Zoli W; Fabbri F; Brigliadori G; Ricotti L; Tesei A; Rosetti M; De Cesare M; Beretta GL; Corna E; Supino R; Zunino F
Neoplasia; 2005 Feb; 7(2):152-61. PubMed ID: 15802020
[TBL] [Abstract][Full Text] [Related]
7. A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo.
Zou J; Li S; Chen Z; Lu Z; Gao J; Zou J; Lin X; Li Y; Zhang C; Shen L
Cell Death Dis; 2018 May; 9(6):661. PubMed ID: 29855512
[TBL] [Abstract][Full Text] [Related]
8. EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Zander SA; Sol W; Greenberger L; Zhang Y; van Tellingen O; Jonkers J; Borst P; Rottenberg S
PLoS One; 2012; 7(9):e45248. PubMed ID: 23028879
[TBL] [Abstract][Full Text] [Related]
9. Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect.
Prada CF; Alvarez-Velilla R; Balaña-Fouce R; Prieto C; Calvo-Álvarez E; Escudero-Martínez JM; Requena JM; Ordóñez C; Desideri A; Pérez-Pertejo Y; Reguera RM
Biochem Pharmacol; 2013 May; 85(10):1433-40. PubMed ID: 23466420
[TBL] [Abstract][Full Text] [Related]
10. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
Oostendorp RL; van de Steeg E; van der Kruijssen CM; Beijnen JH; Kenworthy KE; Schinkel AH; Schellens JH
Drug Metab Dispos; 2009 Apr; 37(4):917-23. PubMed ID: 19139163
[TBL] [Abstract][Full Text] [Related]
11. Subcellular localization of the camptothecin analogues, topotecan and gimatecan.
Croce AC; Bottiroli G; Supino R; Favini E; Zuco V; Zunino F
Biochem Pharmacol; 2004 Mar; 67(6):1035-45. PubMed ID: 15006540
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
13. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
[TBL] [Abstract][Full Text] [Related]
14. Computational Study of Anticancer Drug Resistance Caused by 10 Topisomerase I Mutations, Including 7 Camptothecin Analogs and Lucanthone.
Mulholland K; Wu C
J Chem Inf Model; 2016 Sep; 56(9):1872-83. PubMed ID: 27564845
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P
Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881
[TBL] [Abstract][Full Text] [Related]
17. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
Yamazaki R; Nishiyama Y; Furuta T; Hatano H; Igarashi Y; Asakawa N; Kodaira H; Takahashi H; Aiyama R; Matsuzaki T; Yagi N; Sugimoto Y
Mol Cancer Ther; 2011 Jul; 10(7):1252-63. PubMed ID: 21566063
[TBL] [Abstract][Full Text] [Related]
18. Topotecan is a substrate for multidrug resistance associated protein 4.
Tian Q; Zhang J; Chan SY; Tan TM; Duan W; Huang M; Zhu YZ; Chan E; Yu Q; Nie YQ; Ho PC; Li Q; Ng KY; Yang HY; Wei H; Bian JS; Zhou SF
Curr Drug Metab; 2006 Jan; 7(1):105-18. PubMed ID: 16454695
[TBL] [Abstract][Full Text] [Related]
19. Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4.
Lee HJ; Choi CH
BMC Cancer; 2022 Apr; 22(1):446. PubMed ID: 35461219
[TBL] [Abstract][Full Text] [Related]
20. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]